Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Gray Sheet

Executive Summary

FDA's Goodman named acting chief medical officer: Jesse Goodman is serving as FDA's acting chief medical officer as the agency management realigns to prepare for the new administration's topside leadership team. Goodman, director of the Center for Biologics Evaluation & Research since 2002, was detailed to the CMO post the week of March 9, FDA said. CBER Deputy Director Karen Midthun is now running the biologics center. A virologist by training, Goodman joined FDA in 1998 to direct the interagency task force on antimicrobial resistance. He later moved into CBER, where his work on bioterrorism preparedness brought him into the same orbit as FDA Commissioner-nominee Margaret Hamburg. The two served on several Institute of Medicine panels focused on microbial threats and bioterrorism preparedness in 2002 and 2003. Goodman was also selected as FDA's lone representative on the Federal Coordinating Committee on Comparative Effectiveness Research, appointed by the Department of Health and Human Services March 19

You may also be interested in...

Pandemic-Related Price-Gouging Would Be False, Misleading Advertising Under House, Senate Bills

House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.

COVID-19 Trial Changes Are “Propulsive Force” For Digital Adoption

Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.

Digital Doublespeak: The Language Barrier When Tech Companies Meet Regulators

A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts